Neovacs S.A. (EPA:ALNEV)

Market Cap	95.00 -99.8%
Revenue (ttm)	199.27K -75.8%
Net Income	-4.36M
EPS	-9.14
Shares Out	476.63K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200,036,824
Average Volume	65,554,585
Open	0.0004
Previous Close	0.0002
Day's Range	0.0002 - 0.0004
52-Week Range	0.0002 - 10.9000
Beta	42.05
RSI	26.06
Earnings Date	May 14, 2026

About Neovacs

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IFNα Kinoid, an anti-interferon alpha vaccine which completed Phase I / IIa and IIb clinical trial for the treatment of lupus erythematosus; and Phase II...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 16
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNEV

Financial Performance

In 2024, Neovacs's revenue was 433,937, a decrease of -18.65% compared to the previous year's 533,412. Losses were -32.91 million, 276.4% more than in 2023.